Gallup data suggest GLP-1 injectables are already driving real changes in national obesity rates—even if diabetes still looms ...

Until recently, GLP -1s, a powerful new class of weight-loss drugs, were confined mostly to rich countries. Yet the World ...

Eli Lilly announced that its experimental weight-loss pill, orforglipron, meets most of the criteria for the U.S. Food and ...

A once-a-day pill for obesity could be a cheaper and more accessible weight-loss drug, after a study found the tablet can lead to “significant” reductions in body weight. More than 60 per cent of ...

Semaglutide, the active ingredient in Wegovy and Ozempic, lowers major cardiac event risk, regardless of how much weight a ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to request global regulatory approval this year, the company said Tuesday. The only ...

A new era of weight-loss treatment could soon trade needles for pills. Drugmakers behind GLP-1 injections like Wegovy and Zepbound are racing to launch once-daily oral versions that may help people ...

An oral weight loss pill has performed well in clinical trials, positioning it as a potential alternative to injectable GLP-1 medications like Ozempic and Wegovy. The Eli Lilly drug, called ...

An oral weight loss pill has performed well in clinical trials, positioning it as a potential alternative to injectable GLP-1 medications like Ozempic and Wegovy. The Eli Lilly drug, called ...

Shares of Viking Therapeutics plummeted more than 43% Tuesday after the company revealed poorer-than-expected mid-stage trial data for its experimental weight-loss pill, joining Eli Lilly with similar ...

A pill version of semaglutide — the active ingredient in Ozempic and Wegovy — helped people lose more than 13% of their body weight in a late-stage trial, pharmaceutical giant Novo Nordisk announced ...